These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14744276)

  • 21. Early results after synchronous carotid stent placement and coronary artery bypass graft in patients with asymptomatic carotid stenosis.
    Barrera JG; Rojas KE; Balestrini C; Espinel C; Figueredo A; Saaibi JF; Machuca S; Murcia A
    J Vasc Surg; 2013 Feb; 57(2 Suppl):58S-63S. PubMed ID: 23336857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry].
    Zeymer U; Zahn R; Siegler KE; Senges J
    Herz; 2004 Nov; 29(7):651-5. PubMed ID: 15580318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
    Harrington RA; Kleiman NS; Kottke-Marchant K; Lincoff AM; Tcheng JE; Sigmon KN; Joseph D; Rios G; Trainor K; Rose D
    Am J Cardiol; 1995 Dec; 76(17):1222-7. PubMed ID: 7503000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of eptifibatide for treatment of severe dissections as a bail-out procedure.
    Latsch A; Suselbeck T; Muth N; Poerner T; Baumbach A; Pfleger S; Borggrefe M; Haase KK
    Int J Cardiol; 2004 Aug; 96(2):229-33. PubMed ID: 15262038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
    Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
    N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Peterson JG; Topol EJ; Roe MT; Sapp SK; Lincoff AM; Deckers JW; Blackstone EH; Harrington RA; Califf RM; Lauer MS
    Am J Cardiol; 2001 Mar; 87(5):532-6. PubMed ID: 11230834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of In-Hospital Bleeding and Cardiovascular Events with High-Dose Bolus Tirofiban and Shortened Infusion to Short-Duration Eptifibatide as Adjunctive Therapy for Percutaneous Coronary Intervention.
    Anderson GL; Osborn JL; Nei SD; Bell MR; Barsness GW; Mara KC; Ou NN
    Am J Cardiol; 2019 Jan; 123(1):44-49. PubMed ID: 30539747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of the glycoprotein IIb/IIIa inhibitor eptifibatide in a patient undergoing carotid artery stenting.
    New G; Roubin GS; Iyer SS; Vitek JJ
    J Invasive Cardiol; 2000 Dec; 12 Suppl D():23D-4D. PubMed ID: 11156720
    [No Abstract]   [Full Text] [Related]  

  • 29. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study.
    Hassan W; Al-Sergani H; Al Buraiki J; Dunn B; Al Turki F; Akhras N; Elshaer F; Nawaz M; Kharabsheh S; ElKum N
    Am Heart J; 2007 Aug; 154(2):345-51. PubMed ID: 17643587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
    J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement.
    Sisk J; Palma M; Cooper C; Eltahawy E; Atallah J
    Pain Physician; 2012; 15(6):479-83. PubMed ID: 23159964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
    Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
    Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study.
    Hanefeld C; Sirtl C; Spiecker M; Bojara W; Grewe PH; Lawo T; Mügge A
    Chest; 2004 Sep; 126(3):935-41. PubMed ID: 15364776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
    O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
    Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
    Mandak JS; Blankenship JC; Gardner LH; Berkowitz SD; Aguirre FV; Sigmon KN; Timmis GC; Gilchrist IC; McIvor M; Resar J; Weiner BH; George BS; Talley JD; Lincoff AM; Tcheng JE; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1518-24. PubMed ID: 9626829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.
    Wilczynski M; Wybraniec MT; Milewski K; Sanak M; Wita K; Buldak Ł; Kondys M; Buszman P; Bochenek A
    J Cardiovasc Surg (Torino); 2016 Feb; 57(1):100-10. PubMed ID: 26771733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.